Patent application number | Description | Published |
20080311204 | STABLE ORAL FORMULATION CONTAINING BENZIMIDAZOLE DERIVATIVE - An enteric formulation containing at least one benzimidazole compound, said formulation containing:
| 12-18-2008 |
20100093650 | Pharmaceutical Anit-Infective Composition for Inhalation - A composition for inhalation, comprising at least: a) an effective amount of an antimicrobial aminoglycoside derivative or a salt thereof, and b) an effective amount of a biofilm modifier which is a macrolide derivative or a salt thereof. | 04-15-2010 |
20100300440 | Dry powder inhaler system - The present invention relates to a pharmaceutical composition for inhalation, consisting in a combination of (A) a dry powder formulation containing a micronized active ingredient, alone or mixed with an inactive ingredient, said powder being filled in a hydroxypropylmethylcellulose (HPMC) capsule and (B) a single dose dry powder inhaler device especially adapted to said capsule to provide a high respiratory dose of said active ingredient when said drug is inhaled by the mouth through said device. Said device being characterized in that he is equipped with piercing is needles or pins (in order to pierce the capsule) of diameter of not less than 0.8 mm preferably not less than 1 mm. | 12-02-2010 |
20130096196 | PHARMACEUTICAL SEMI-SOLID COMPOSITION OF ISOTRETINOIN - An oral pharmaceutical composition of isotretinoin containing at least two lipidic excipients, one of them being hydrophilic (i.e. having an HLB value superior or equal to 10), the other being an oily vehicle | 04-18-2013 |
20130158119 | PHARMACEUTICAL SEMI-SOLID COMPOSITION OF ISOTRETINOIN - Pharmaceutical semi-solid composition of Isotretinoin An oral pharmaceutical composition of isotretinoin containing at least two lipidic excipients, one of them being hydrophilic (i.e. having an HLB value superior or equal to 10), the other being an oily vehicle | 06-20-2013 |
20150017244 | DRY POWDER FORMULATION OF AZOLE DERIVATIVE FOR INHALATION - A spray dried-powder composition for inhalation comprising particles (X) containing (a) between 5 and 50% by weight of at least one azole derivative in amorphous state but not in crystalline structure and (b) at least one matricial agent to the composition selected from a group consisting of polyol such as sorbitol, mannitol and xylitol; a monosaccharides such as glucose and arabinose; disaccharide such as lactose, maltose, saccharose and dextrose; cholesterol, and any mixture thereof, wherein the composition provides a dissolution rate of said azole derivative of at least, 5% within 10 minutes, 10% within 20 minutes and 40% within 60 minutes when tested in the dissolution apparatus type 2 of the United States Pharmacopoeia at 50 rotation per minute, 37° C. in 900 milliliters of an aqueous dissolution medium adjusted at pH 1.2 and containing 0.3% of sodium laurylsulfate. | 01-15-2015 |
20150037414 | Stable controlled release pharmaceutical compositions containing fenofibrate and pravastatin - A controlled Release Pharmaceutical composition comprising an effective amount of Pravastatin and Fenofibrate, characterised in that the difference, in absolute value, between the times of maximal concentration (T | 02-05-2015 |